CliffBio
small molecule

POLYMYXIN B SULFATE

POLYMYXIN B SULFATE

Loss of exclusivity—loss of exclusivity
CompanyFresenius Kabi →See this company's full patent-cliff portfolio

Drug detail

Brand namePOLYMYXIN B SULFATE
Active ingredientPOLYMYXIN B SULFATE
StrengthEQ 500,000 UNITS BASE/VIAL
Dosage formINJECTABLE
RouteINJECTION
ModalitySmall molecule
FDA approvalJanuary 2008
Marketing statusRX

More from Fresenius Kabi

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.